Richard D. Caldwell
Foghorn Therapeutics (United States) · 19 works · 805 citations · h-index 11
Top works
- Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
- Crystallographic structure of a small molecule SIRT1 activator-enzyme complex
- Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
- Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064
- FXR agonist activity of conformationally constrained analogs of GW 4064
- Btk inhibition treats TLR7/IFN driven murine lupus
- Discovery of 6,7-Dihydro-5H-pyrrolo[2,3-a]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists
- Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit
- Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression
- Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk
- Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors
- Discovery of Affinity‐Based Probes for Btk Occupancy Assays
- Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors
- Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists
- Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity
- TO MARKET, TO MARKET–2021: SMALL MOLECULES
- Abstract 5792: Identification of first in class selective ARID1B degraders
- Venture Out of Your Comfort Zone
- Design Strategies for Second-Generation Irreversible Covalent Inhibitors of Bruton’s Tyrosine Kinase